Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CGRP inhibitors

- PMLiVE

Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray

Royalty Pharma signed a deal for the programme in 2020 with Biohaven, which Pfizer has since acquired

- PMLiVE

Pfizer to acquire Biohaven in deal worth over $11bn

The deal will expand Pfizer’s Internal Medicine pipeline

Biogen Idec building

ICER says price of Biogen’s Aduhelm should be much lower

US cost-effectiveness watchdog’s analysis estimates current annual list price of $56,000 could be reduced to $3,000 to $8,400

- PMLiVE

ICER to review the role of health insurers in determining patient access to prescription drugs

Non-profit research institute will evaluate how health insurance policies may harm patient access to treatment

- PMLiVE

ICER extends evaluation of Biogen’s aducanumab after FDA delay

FDA delayed its decision on potential Alzheimer's therapy to 7 June

Infographic

Migraine market snapshot

Research Partnership

- PMLiVE

Biohaven gets FDA approval for migraine drug Nurtec ODT

Becomes second drugmaker to bring an oral CGRP inhibitor to US market

- PMLiVE

Lilly launches migraine med Reyvow at $640 per eight-pill pack

Enters increasingly competitive market

- PMLiVE

AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER

Updated draft evidence report maintains the benefit is small with higher price tag

- PMLiVE

ICER closely monitoring FDA’s Zolgensma investigation

Could affect initial cost assessment

- PMLiVE

Eli Lilly scores positive phase 3 results for Emgality in treatment resistant migraine

Hopes to catch up with rivals in the market

- PMLiVE

New efficacy data boosts Aimovig’s migraine market lead

Data should help boost uptake

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links